Physician profile
Cherry Mathew
NPI 1174589790
$4,919.67
in general payments reported to CMS, 2019-2025
35 companies · $608 in 2025
The $608 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $1,315 · 2021: $676 · 2022: $454 · 2023: $536 · 2024: $433 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.26 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $567.47 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $417.27 | 2019-2024 | Nuplazid |
| Jazz Pharmaceuticals INC. | $398.54 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $372.34 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $264.92 | 2019-2020 | |
| Lilly USA, LLC | $235.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $233.91 | 2019-2025 | |
| Sk Life Science, INC. | $233.83 | 2020-2024 | |
| Eisai INC. | $202.61 | 2019-2021 | |
| Emd Serono, INC. | $196.41 | 2019-2020 | |
| Amgen INC. | $139.18 | 2019-2022 | |
| Ucb, INC. | $135.32 | 2019-2025 | Fintepla |
| Amneal Pharmaceuticals LLC | $98.42 | 2019-2021 | |
| Ceribell, INC. | $86.16 | 2025 | Pocket Eeg Device |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $78.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $58.33 | 2023-2024 | Rexulti |
| Aquestive Therapeutics, INC. | $58.27 | 2020 | |
| Ge Healthcare | $43.86 | 2019-2020 | |
| Genzyme Corporation | $41.61 | 2019-2020 | |
| Kyowa Kirin, INC. | $39.80 | 2020-2021 | |
| Csl Behring | $36.18 | 2020-2021 | |
| Acorda Therapeutics, INC | $34.06 | 2019 | |
| Neurelis, INC. | $33.78 | 2020 | |
| Biogen, INC. | $33.40 | 2019-2022 | |
| Greenwich Biosciences, INC. | $32.52 | 2019 | |
| Lundbeck LLC | $29.39 | 2020-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $24.78 | 2020-2021 | |
| Impel Pharmaceuticals INC. | $21.01 | 2022 | |
| Livanova USA, INC. | $18.60 | 2019 | |
| Ani Pharmaceuticals, INC. | $16.08 | 2023 | Purified Cortrophin Gel |
| Argenx US, INC. | $16.06 | 2023 | Vyvgart |
| Mdd US Operations, LLC | $14.79 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.67 | 2020 | |
| Resmed Corp | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherry Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.